- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Lupin arm unveils heart drug in Canada
Montreal: Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited has announced the launch of Propranolol LA (long-acting) capsules, 60 mg, 80 mg, 120 mg and 160 mg, in Canada.
Propranolol LA is a generic equivalent of Inderal LA, it provides an effective treatment solution since the discontinuation of Inderal LA for patients and healthcare practitioners.
The medicine is a beta-blocker used to treat hypertension, angina, tremors, heart rhythm disorders, and other heart or circulatory conditions.
"Propranolol LA’s launch caters to the needs of Canadian patients, reaffirming Lupin's commitment to enhancing healthcare access and affordability. The launch of Propranolol LA, the sole extended-release formulation of Propranolol accessible to Canadian patients following the discontinuation of Inderal LA, has led to significant progress in fulfilling patient unmet needs. This extended-release variant not only ensures consistent alleviation of symptoms but also enhances patient adherence and overall quality of life. Lupin encourages patients to consult healthcare practitioners or pharmacists regarding the transition to Propranolol LA," the Company stated.
“We are delighted to announce the launch of Propranolol LA capsules for patients in Canada. We have diligently worked to build our portfolio to include Propranolol LA ensuring patients have access to the essential medicines. This launch signifies our commitment to fostering healthcare solutions that truly make a difference,” said Dr. Sofia Mumtaz, President – Legal, Canada, Australia, and Japan, Lupin.
Read also: Lupin bags USFDA okay for idiopathic pulmonary fibrosis drug Pirfenidone
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751